AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Military and Veterans

0

There is significant variation in the presentation of PTSD between patients. Eighty percent have at least one additional comorbidity such as depression, anxiety, or a substance abuse disorder, further complicating diagnosis and treatment1. Despite the societal, financial, and emotional pressure that PTSD places on patients, treatment options remain scarce, with only two therapies approved by the FDA. To advance treatment options and patient care, the PTSD-DT Program APT will evaluate the effect of each therapy on a patient’s PTSD symptoms over 12 weeks. Since medication adherence has always been an important methodological issue in PTSD clinical trials, AiCure’s adherence platform will provide patients with the support needed to ensure correct dosing. AiCure’s digital biomarker solution will remotely detect subtle changes in a patient’s response to treatment by capturing and analyzing audio and video data, determining changes in emotional expressiveness, physical movements, patterns speaking and more. By frequently gathering sensitive and objective information and accurately measuring treatment adherence, AiCure can help identify the right medication for the right patient or allow clinicians to intervene in a patient’s treatment plan in a timely manner. if the drug is not likely to be effective.

“Strong evidence to tailor therapeutic interventions to individual patient needs remains the greatest unmet need in PTSD research today, but AI has the potential to advance precision medicine,” said the dr. Ed Ikeguchi, CEO of AiCure. “By achieving unimaginable levels of specificity when assessing a patient’s well-being, we can personalize their care and improve their quality of life. This innovative trial with the PTSD-DT program illustrates our shared commitment to rewrite the PTSD care scenario – an area that has remained largely stagnant for decades.”

Accelerating PTSD research with new trial design

While most of these PTSD studies have historically evaluated one drug at a time, the PTSD-DT program will instead rely on an innovative trial design to simultaneously test multiple potential PTSD treatments through a multicenter randomized approach and multi-arm. With support from AiCure, the trial will also uniquely interrogate the biological and environmental factors that underlie a treatment’s effectiveness, allowing non-effective treatments to be identified more quickly. While APTs are increasingly used to treat complex disorders in other disease areas, their use is new in psychiatry.

“PTSD has plagued our service members for decades, yet the drug treatments available are not as effective as we would like. There is an urgent need to improve unit preparedness and reduce its adverse effects on our service members with PTSD, and developing targeted treatments will address this need,” said Dr. Kimberly del Carmen, the product manager for the U.S. Army Medical Equipment Development Activity (USAMMDA), which manages the DHA PTSD-DT program. “AiCure is a critical partner in this study as we aim to unlock the key to precision medicine in PTSD, by understanding the nuances of a patient’s behavior and, in the future, giving us the information needed to correct proactively the course if necessary.

About AiCure, LLC

AiCure is an advanced artificial intelligence and data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs, and accelerates timelines through remote patient engagement and assessments, including digital biomarker measurement and real-time patient dosage monitoring. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has over 75 issued patents and works with global customers in over 45 countries. AiCure is globally recognized and has received the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.

About the U.S. Army Medical Equipment Development Activity

USAMMDA is a subordinate command of the U.S. Army Medical Research and Development Command, under Army Futures Command. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for the development and delivery of mission-critical products designed to protect and preserve the lives of warfighters around the world. These products include drugs, vaccines, biologicals, devices and medical support equipment intended to maximize casualty survival on the battlefield.

About the Defense Health Agency

The Defense Health Agency is a joint strategic combat support agency that enables uniformed medical services to provide a medically ready force and medically ready force to combatant commands in peacetime and wartime. The DHA supports the military strategy and service departments of national defense by directing the military health system as an integrated and highly reliable system of medical readiness, training and health. DHA leads a research and acquisitions business to guide innovative hardware and knowledge products from concept through development and sustaining the final product, in the hands of vendors and warfighters.

1 American family physician. Diagnosis and management of post-traumatic stress disorder. https://www.aafp.org/afp/2003/1215/p2401.html

SOURCEAiCure

Share.

Comments are closed.